LTFU for All Cell and Gene Therapy Studies

Not yet recruitingOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

November 29, 2041

Study Completion Date

November 29, 2041

Conditions
Hepatocellular CarcinomaProstate Cancer
Interventions
BIOLOGICAL

AZD5851

Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.

BIOLOGICAL

AZD0754

Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.

Trial Locations (25)

3002

Research Site, East Melbourne

10065

Research Site, New York

15237

Research Site, Pittsburgh

19104

Research Site, Philadelphia

20007

Research Site, Washington D.C.

30322

Research Site, Atlanta

32224

Research Site, Jacksonville

33612

Research Site, Tampa

43210

Research Site, Columbus

55905

Research Site, Rochester

63110

Research Site, St Louis

66205

Research Site, Westwood

77030

Research Site, Houston

85054

Research Site, Phoenix

91010

Research Site, Duarte

92868

Research Site, Orange

94143

Research Site, San Francisco

97239

Research Site, Portland

07601

Research Site, Hackensack

227-8577

Research Site, Kashiwa

606-8507

Research Site, Kyoto

589-8511

Research Site, Osakasayama-shi

03080

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY